Related Experiment Video
Updated: Jun 29, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives?
1Gastroenterology Division, University of Minnesota, Minneapolis, MN 55455, USA. lakex009@tc.umn.edu
Summary
Liver transplantation offers excellent outcomes for hepatitis patients. Combination antiviral nucleoside/nucleotide therapies now provide effective prevention against hepatitis B re-infection post-transplant.
Area of Science:
- Hepatology
- Transplantation Medicine
- Virology
Background:
- Liver transplantation is a curative option for end-stage liver disease.
- Hepatitis B virus (HBV) recurrence remains a significant challenge post-transplantation.
- Achieving excellent outcomes hinges on preventing HBV re-infection.
Purpose of the Study:
- To evaluate the efficacy of current strategies for preventing HBV re-infection after liver transplantation.
- To compare the effectiveness and limitations of hepatitis B immunoglobulin (HBIG) with newer antiviral therapies.
Main Methods:
- Review of existing literature on liver transplantation for hepatitis B.
- Analysis of data on the use of hepatitis B immunoglobulin (HBIG) for prophylaxis.
- Assessment of the efficacy of combination nucleoside/nucleotide antiviral agents in preventing HBV recurrence.
Main Results:
- Liver transplantation provides the best outcomes for patients with hepatitis B compared to other diagnoses.
- Hepatitis B immunoglobulin (HBIG) is effective but associated with high costs and potential side effects.
- Combination nucleoside/nucleotide antiviral therapies demonstrate effective prophylaxis against HBV re-infection.
Conclusions:
- Successful liver transplantation for hepatitis B is achievable with optimal management.
- Preventing HBV re-infection is paramount for long-term graft and patient survival.
- Combination nucleoside/nucleotide antivirals represent a cost-effective and well-tolerated strategy for HBV prophylaxis.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...